Jun 5, 2022 · In the first trial of its kind, patients were given T-DXd (also known as Enhertu®), which targets a protein called HER2. The results showed that those who received T-DXd did significantly better than those who received standard chemotherapy. The targeted drug held their cancer in check nearly twice as long and increased their survival by about 35%.

Jul 5, 2022 · Trastuzumab deruxtecan, also known as T-DXd, “is the first HER2- targeted therapy shown to provide clinically meaningful improvement in progression-free and overall survival compared with standard chemotherapy in people with HER2-low metastatic breast cancer,” Dr. Modi said at the meeting.

Findings identify new target that will change treatment for some with hormone receptor -positive metastatic breast cancer. A new study of trastuzumab deruxtecan or TDX-d (Enhertu) is very likely to change the standard of care for many people with metastatic breast cancer.

Oct 23, 2023 · Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)–directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non–small-cell lung cancer. Treatments are limited for other HER2-expressing solid tumors.

Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan). [11][12] It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenoc...

Dec 7, 2022 · SAN ANTONIO – Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with trastuzumab emtansine (T-DM1), according to results from the phase III DESTINY-Breast02 trial presented...

Aug 5, 2022 · Findings from the phase III DESTINY-Breast04 trial indicate that the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is effective for patients with inoperable/metastatic HER2-low breast cancer. T-DXd should be considered a new standard of care for these patients, who otherwise have limited options.

Jul 25, 2023 · In this ESMO Expert Consensus Statement (ECS), 1 the best role for trastuzumab deruxtecan (T-DXd) in the treatment of human epidermal growth factor receptor 2 (HER2)-low metastatic triple-negative breast cancer (TNBC) was discussed.

We reviewed characteristics of patients who developed T-DXd–related ILD/pneumonitis and its patterns, produced multidisciplinary guidelines on diagnosis and management, and described areas for future investigation.

May 12, 2023 · Now, data from the phase III DESTINY-Breast02 trial provide evidence supporting the use of T-DXd in this setting. A total of 608 patients with metastatic HER2-positive breast cancer and disease...